Recognise asbestos-related pleural malignancy, obtain adequate image-guided or thoracoscopic tissue, control recurrent effusion and pain and coordinate systemic, local, occupational and palliative care.
Malignant pleural mesothelioma arises from pleural mesothelial cells after durable mineral-fibre exposure, most commonly asbestos. Occupational exposure may have occurred during cutting, lagging, drilling, demolition, ship repair or maintenance rather than through a job title labelled asbestos worker. Family exposure from contaminated clothing and environmental exposure also occur. Latency is commonly 30 to 50 years, so a retired person may not connect present symptoms with work early in adult life. Smoking does not cause mesothelioma, although it adds separate lung-cancer risk.
Tumour grows along the pleural surface rather than as one rounded pulmonary mass. Effusion, nodular thickening and a rind encase the lung, restrict expansion and invade intercostal nerves, chest wall, diaphragm and mediastinum. Persistent unilateral pain can be more prominent than breathlessness. Pleural plaques demonstrate prior asbestos exposure but are benign and do not prove that a new effusion is mesothelioma. Conversely, absence of plaques cannot exclude exposure or cancer.
Inhaled amphibole and chrysotile fibres from construction, shipbuilding, insulation and industrial work create risk after a latency commonly measured in decades.
Family members exposed to contaminated work clothing and communities near asbestos industry may develop mesothelioma without direct employment in a high-risk trade.
Naturally occurring erionite and other durable fibres cause mesothelial carcinogenesis in specific geographical and exposure settings.
Germline BAP1 tumour-predisposition syndrome is rare but increases mesothelioma and other cancer risk and may justify genetics assessment.
Long biopersistent fibres migrate to pleural surfaces, resist clearance and repeatedly injure mesothelial cells and resident macrophages.
Reactive oxygen species, cytokines and repeated repair promote genomic instability over decades after exposure has ceased.
Loss involving BAP1, CDKN2A and NF2 permits mesothelial survival, proliferation and altered chromatin and contact-inhibition signalling.
Diffuse tumour spreads along pleura, encases lung, invades chest wall and diaphragm and produces fluid, pain, trapped lung and restrictive ventilatory failure.
Progressive breathlessness, reduced expansion and breath sounds, dull percussion and recurrent fluid suggests a unilateral pleural process requiring imaging.
Persistent local or circumferential pain, night pain and neuropathic intercostal radiation reflects parietal pleural and chest-wall invasion.
Nodular circumferential pleural thickening, fissural involvement and contraction of the hemithorax is strongly suspicious but still needs tissue.
Failure of lung re-expansion after drainage, persistent pneumothorax space or pain with fluid removal indicates visceral pleural restriction.
Acute hypoxaemia, severe pain, bleeding or sepsis after biopsy, drain or catheter requires urgent pleural and surgical assessment.
Weight loss, cachexia, thrombosis, abdominal involvement or distant metastasis indicates advanced burden and narrows local treatment benefit.
Lung, breast and other adenocarcinomas commonly involve pleura; immunohistochemical panels distinguish epithelial lineage from mesothelial differentiation.
Pleural plaques, diffuse benign thickening and rounded atelectasis indicate exposure but do not themselves establish mesothelioma.
Fever, inflammatory fluid and pleural thickening can mimic malignancy; microbiology and histology are important when epidemiology or immune status supports infection.
Inflamed pleura can show atypical mesothelial cells in fluid or small biopsy; invasion and molecular adjuncts may be needed for confident malignancy.
Fluid reaccumulates while visceral pleural tumour prevents expansion, limiting pleurodesis and causing repeated breathlessness and procedure burden.
Tumour invades intercostal nerves, ribs and procedure tracts, producing mixed nociceptive and neuropathic pain with sleep and movement impairment.
A thick pleural rind, effusion, atelectasis and diaphragm invasion reduce ventilation and exercise capacity and can lead to oxygen dependence.
Inflammation, immobility and advanced cancer increase VTE, cachexia, fatigue and loss of independence during progressive pleural disease.
Calcified pleural plaques support past asbestos contact but are benign and neither prove nor exclude a separate malignant pleural process.
Mesothelioma may shed few diagnostic cells and invasion cannot be assessed reliably in fluid, so adequate pleural tissue is often necessary.
Talc cannot fuse surfaces when tumour prevents the lung reaching the chest wall, making an indwelling catheter more effective in trapped lung.
Talc produces long-lasting inflammatory avidity that can confuse later staging, so obtain decision-changing PET beforehand when feasible.
People may not recognise asbestos by name, but drilling board, removing lagging or washing dusty clothes can reveal meaningful exposure.
Treating pleural plaques as proof that a new effusion is mesothelioma.
Excluding mesothelioma from one negative cytology result.
Obtaining a superficial or necrotic biopsy that cannot show invasion or subtype.
Performing pleurodesis without checking that the lung re-expands.
Requesting PET immediately after talc and interpreting inflammatory uptake as tumour stage.
Offering radical surgery as routine without specialist selection and evidence discussion.
Waiting until anticancer treatment ends before addressing chest-wall pain, breathlessness and occupational support.
Your practice draft is saved in this browser.
A retired insulation worker has recurrent unilateral exudative effusion and nodular pleural thickening on contrast CT, but the first cytology is negative. What is the best next diagnostic step if fit?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
Care integrates fluid control, systemic treatment and symptom support. Talc pleurodesis needs pleural apposition and therefore works poorly in trapped lung; an indwelling pleural catheter allows ambulatory intermittent drainage and may produce spontaneous pleurodesis. Systemic therapy may use platinum-pemetrexed or immunotherapy under current NICE guidance. Extensive radical surgery carries high morbidity and is not routine outside tightly selected specialist or research settings. Pain often needs opioid, neuropathic treatment, radiotherapy and specialist procedures, while compensation and industrial-disease support should be offered sensitively.
Give folic acid and vitamin B12 supplementation and dexamethasone skin prophylaxis exactly as the product protocol; monitor marrow, renal function, infection, mucositis, rash, fatigue and emesis.
Dual checkpoint blockade increases immune lung, bowel, liver, endocrine, skin, cardiac, renal and neurological toxicity; review autoimmunity, transplant, infection and steroid requirements and provide urgent contact education.
Prescribe laxative and antiemetic when indicated, review sedation, respiration and driving and reduce or select another opioid in renal impairment; pain progression still requires structural reassessment.